Chronic Kidney Disease Therapeutics
1. Fosrenol patent expiration
Treatment: Reduction of serum phosphate; Reduction of serum phosphate in patients with end stage renal disease
FOSRENOL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5968976 | TAKEDA PHARMS USA | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
Oct, 2018
(7 years ago) | |
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(1 year, 4 months ago) | |
| US7465465 | TAKEDA PHARMS USA | Pharmaceutical formulation comprising lanthanum compounds |
Aug, 2024
(1 year, 4 months ago) | |
| US8980327 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(4 years from now) | |
| US9023397 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(4 years from now) | |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 23 November, 2005
Dosage: POWDER; TABLET, CHEWABLE
How can I launch a generic of FOSRENOL before it's drug patent expiration?
More Information on Dosage
FOSRENOL family patents
2. Jesduvroq patent expiration
Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11117871 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(12 years from now) | |
| US11643397 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(1 year, 5 months from now) | |
| US8324208 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815884 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(1 year, 5 months from now) | |
| US8557834 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(1 year, 5 months from now) | |
| US11649217 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 01, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 01 February, 2027
Market Authorisation Date: 01 February, 2023
Dosage: TABLET
More Information on Dosage
JESDUVROQ family patents
3. Kerendia patent
expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE49826 | BAYER HLTHCARE | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
Jul, 2035
(9 years from now) | |
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-279) | Sep 01, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 09, 2026 |
| New Indication(I-970) | Jul 11, 2028 |
| New Strength(NS) | Jul 11, 2028 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 09 July, 2025
Market Authorisation Date: 09 July, 2021
Dosage: TABLET
More Information on Dosage
KERENDIA family patents
4. Korsuva patent expiration
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10793596 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| US7727963 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| US10017536 | VIFOR INTL | Synthetic peptide amides and dimers thereof |
Nov, 2027
(1 year, 10 months from now) | |
| US8536131 | VIFOR INTL | Synthetic peptide amides and dimers thereof |
Nov, 2027
(1 year, 10 months from now) | |
| US7713937 | VIFOR INTL | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(1 year, 10 months from now) | |
| US7402564 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10138270 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| US8486894 | VIFOR INTL | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(1 year, 10 months from now) | |
| US8217007 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| US9334305 | VIFOR INTL | Synthetic peptide amides and dimers thereof |
Nov, 2027
(1 year, 10 months from now) | |
| US9359399 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| US8236766 | VIFOR INTL | Uses of synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 23 August, 2025
Market Authorisation Date: 23 August, 2021
Dosage: SOLUTION
More Information on Dosage
KORSUVA family patents
5. Omontys patent expiration
Treatment: Treatment of anemia due to chronic kidney disease
Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 7 months ago) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 7 months ago) | |
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 7 months ago) | |
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(1 year, 7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(4 months from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(4 months from now) | |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Dosage: SOLUTION
More Information on Dosage
OMONTYS family patents
6. Sensipar patent expiration
Treatment: Method of decreasing or reducing parathyroid hormone level; Method of modulating parathyroid hormone secretion; Method of treating hyperparathyroidism; Method of reducing serum ionized calcium level; ...
SENSIPAR's oppositions filed in EPO
SENSIPAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6031003 | AMGEN | Calcium receptor-active molecules |
Dec, 2016
(9 years ago) | |
| US6211244 | AMGEN | Calcium receptor-active compounds |
Oct, 2015
(10 years ago) | |
| US6011068 | AMGEN | Calcium receptor-active molecules |
Mar, 2018
(7 years ago) | |
| US6313146 | AMGEN | Calcium receptor-active molecules |
Dec, 2016
(9 years ago) | |
| US7829595 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(8 months from now) | |
| US9375405 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-634) | Feb 25, 2014 |
| M(M-101) | Feb 25, 2014 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2018 |
| Orphan Drug Exclusivity(ODE-8) | Feb 25, 2018 |
| M(M-200) | May 23, 2020 |
| Orphan Drug Exclusivity(ODE-78) | Nov 21, 2021 |
Drugs and Companies using CINACALCET HYDROCHLORIDE ingredient
Market Authorisation Date: 08 March, 2004
Dosage: TABLET
How can I launch a generic of SENSIPAR before it's drug patent expiration?
More Information on Dosage
SENSIPAR family patents
7. Vafseo patent expiration
Treatment: Treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8598210 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(1 year, 5 months from now) | |
| US11065237 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(8 years from now) | |
| US8343952 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Aug, 2027
(1 year, 7 months from now) | |
| US7811595 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Mar, 2028
(2 years from now) | |
| USRE47437 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(1 year, 5 months from now) | |
| US9701636 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(8 years from now) | |
| US10149842 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857543 | AKEBIA | Compositions and methods for treating anemia |
Jun, 2034
(8 years from now) | |
| US11844756 | AKEBIA | Compositions and methods for treating anemia |
Mar, 2036
(10 years from now) | |
| US9987262 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(8 years from now) | |
| US8940773 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(1 year, 5 months from now) | |
| US8323671 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Apr, 2028
(2 years from now) | |
| US11324734 | AKEBIA | Compositions and methods for treating anemia |
Mar, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2029 |
Drugs and Companies using VADADUSTAT ingredient
NCE-1 date: 27 March, 2028
Market Authorisation Date: 27 March, 2024
Dosage: TABLET
More Information on Dosage
VAFSEO family patents